Diabetes Metab J.  2022 Nov;46(6):923-935. 10.4093/dmj.2021.0346.

Fasting Glucose Variability and the Risk of Dementia in Individuals with Diabetes: A Nationwide Cohort Study

• Lee DY
• Kim J
• Park S
• Park SY
• Yu JH
• Seo JA
• Kim NH
• Yoo HJ
• Kim SG
• Choi KM
• Baik SH
• Han K
• Kim NH

• KMID: 2536150
• DOI: http://doi.org/10.4093/dmj.2021.0346

Abstract

Background
We investigated whether fasting glucose (FG) variability could predict the risk of dementia.
Methods
This cohort study analyzed data from Koreans with diabetes after at least three health examinations by the Korean National Health Insurance Corporation between 2005 and 2010, which included at least one examination between 2009 and 2010. A total of 769,554 individuals were included, excluding those aged <40 years and those with dementia. FG variability was measured using the variability independent of the mean (FG-VIM). The incidence of dementia was defined by the International Classification of Diseases 10th Revision codes and prescription of anti-dementia medication and was subdivided into Alzheimer’s disease (AD) and vascular dementia (VD).
Results
During the 6.9-year follow-up, 54,837, 41,032, and 6,892 cases of all-cause dementia, AD, and VD, respectively, were identified. Cox proportional regression analyses showed that as the FG-VIM quartile increased, the risk of dementia serially increased after adjustment for metabolic factors, income status, and diabetes-related characteristics, including the mean FG. Participants in FG-VIM quartile 4 showed a 18%, 19%, and 17% higher risk for all-cause dementia, AD, and VD, respectively, than those in quartile 1; this particularly included non-obese patients with a longer duration of diabetes, high FG levels, dyslipidemia, and those taking glucose-lowering medications. Conversely, the baseline FG status and dementia showed a U-shaped association.
Conclusion
Increased FG variability over 5 years can predict the risk of dementia in individuals with diabetes in Korea. This finding was more pronounced in patients with less favorable metabolic profiles.

Keyword

Alzheimer disease; Dementia; Dementia, vascular; Diabetes mellitus; Glucose

Figure

• 

Reference

1. World Health Organization: Dementia. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia (updated 2021 Sep 2).

2. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017; 390:2673–734.

3. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig. 2013; 4:640–50.

4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006; 5:64–74.

5. Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019; 55:100944.

6. Kim YG, Park DG, Moon SY, Jeon JY, Kim HJ, Kim DJ, et al. Hypoglycemia and dementia risk in older patients with type 2 diabetes mellitus: a propensity-score matched analysis of a population-based cohort study. Diabetes Metab J. 2020; 44:125–33.

7. Nam GE, Park YG, Han K, Kim MK, Koh ES, Kim ES, et al. BMI, weight change, and dementia risk in patients with newonset type 2 diabetes: a nationwide cohort study. Diabetes Care. 2019; 42:1217–24.

8. Lee SH, Han K, Cho H, Park YM, Kwon HS, Kang G, et al. Variability in metabolic parameters and risk of dementia: a nationwide population-based study. Alzheimers Res Ther. 2018; 10:110.

9. Ernst ME, Ryan J, Chowdhury EK, Margolis KL, Beilin LJ, Reid CM, et al. Long-term blood pressure variability and risk of cognitive decline and dementia among older adults. J Am Heart Assoc. 2021; 10:e019613.

10. Zhong Y, Zhang XY, Miao Y, Zhu JH, Yan H, Wang BY, et al. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomed Environ Sci. 2012; 25:1–7.

11. Rizzo MR, Marfella R, Barbieri M, Boccardi V, Vestini F, Lettieri B, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care. 2010; 33:2169–74.

12. Li TC, Yang CP, Tseng ST, Li CI, Liu CS, Lin WY, et al. Visit-tovisit variations in fasting plasma glucose and HbA1c associated with an increased risk of Alzheimer disease: Taiwan Diabetes Study. Diabetes Care. 2017; 40:1210–7.

13. Zheng B, Su B, Price G, Tzoulaki I, Ahmadi-Abhari S, Middleton L. Glycemic control, diabetic complications, and risk of dementia in patients with diabetes: results from a large U.K. cohort study. Diabetes Care. 2021; 44:1556–63.

14. Lee YH, Han K, Ko SH, Ko KS, Lee KU; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Data analytic process of a nationwide population-based study using National Health Information Database established by National Health Insurance Service. Diabetes Metab J. 2016; 40:79–82.

15. Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, et al. Background and data configuration process of a nationwide population-based study using the Korean National Health Insurance System. Diabetes Metab J. 2014; 38:395–403.

16. O’Brien JT, Burns A; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011; 25:997–1019.

17. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375:895–905.

18. Oh JY, Yang YJ, Kim BS, Kang JH. Validity and reliability of Korean version of International Physical Activity Questionnaire (IPAQ) short form. J Korean Acad Fam Med. 2007; 28:532–41.

19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.

20. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145:247–54.

21. Bancks MP, Carnethon MR, Jacobs DR Jr, Launer LJ, Reis JP, Schreiner PJ, et al. Fasting glucose variability in young adulthood and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes Care. 2018; 41:2579–85.

22. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006; 67:235–40.

23. Yu ZB, Zhu Y, Li D, Wu MY, Tang ML, Wang JB, et al. Association between visit-to-visit variability of HbA1c and cognitive decline: a pooled analysis of two prospective population-based cohorts. Diabetologia. 2020; 63:85–94.

24. Rawlings AM, Sharrett AR, Mosley TH, Ballew SH, Deal JA, Selvin E. Glucose peaks and the risk of dementia and 20-year cognitive decline. Diabetes Care. 2017; 40:879–86.

25. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014; 2:246–55.

26. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018; 14:168–81.

27. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57:1349–54.

28. Russo VC, Higgins S, Werther GA, Cameron FJ. Effects of fluctuating glucose levels on neuronal cells in vitro. Neurochem Res. 2012; 37:1768–82.

29. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. Am J Pathol. 2009; 175:2089–98.

30. Moin AS, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia. J Transl Med. 2021; 19:131.

31. Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: nationwide population-based cohort study. Medicine (Baltimore). 2016; 95:e4018.

32. Xu D, Fang H, Xu W, Yan Y, Liu Y, Yao B. Fasting plasma glucose variability and all-cause mortality among type 2 diabetes patients: a dynamic cohort study in Shanghai, China. Sci Rep. 2016; 6:39633.

33. Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in glycated hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care cohort study. Diabetes Care. 2019; 42:2237–46.

34. Yano Y. Visit-to-visit blood pressure variability: what is the current challenge? Am J Hypertens. 2017; 30:112–4.

35. Yamada M, Mimori Y, Kasagi F, Miyachi T, Ohshita T, Sudoh S, et al. Incidence of dementia, Alzheimer disease, and vascular dementia in a Japanese population: Radiation Effects Research Foundation adult health study. Neuroepidemiology. 2008; 30:152–60.

36. Li S, Yan F, Li G, Chen C, Zhang W, Liu J, et al. Is the dementia rate increasing in Beijing?: prevalence and incidence of dementia 10 years later in an urban elderly population. Acta Psychiatr Scand. 2007; 115:73–9.

37. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia: the Rotterdam Study. Am J Epidemiol. 1998; 147:574–80.

38. Lee YB, Han K, Park S, Kim SM, Kim NH, Choi KM, et al. Gamma-glutamyl transferase variability and risk of dementia: a nationwide study. Int J Geriatr Psychiatry. 2020; 35:1105–14.

39. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004; 35(11 Suppl 1):2620–2.

40. Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015; 11:332–84.

41. American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care. 2021; 44(Suppl 1):S40–52.

42. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021; 44(Suppl 1):S73–84.